Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN BAUER

Allopathic & Osteopathic Physicians Family Medicine

NPI
1053402875
CMS profile
319814
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$3,801.86

213 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,801.86 213

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 213 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN BAUER

NPI 1053402875 · CMS profile ID 319814

Allopathic & Osteopathic Physicians / Family Medicine

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 213 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1053402875?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN BAUER, NPI 1053402875, CMS profile ID 319814. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 213 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1053402875?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). STEVEN BAUER, NPI 1053402875, CMS profile ID 319814. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 213 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1053402875?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
STEVEN BAUER, NPI 1053402875, CMS profile ID 319814, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 213 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1053402875?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

213 matching records · $3,801.86 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 213 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 213.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $16.0507/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811040441 CMS
SANOFI-AVENTIS U.S. LLC $21.1107/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843527801 CMS
Biohaven Pharmaceuticals, Inc. $28.4407/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852419941 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.1507/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763697552 CMS
Novo Nordisk Inc $15.6407/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811158189 CMS
AstraZeneca Pharmaceuticals LP $15.1607/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829635029 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.4707/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819861517 CMS
Esperion Therapeutics, Inc. $29.0607/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838244329 CMS
Clarus Therapeutics Inc. $14.8307/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855025531 CMS
ARBOR PHARMACEUTICALS, INC. $17.8707/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830937887 CMS
Novo Nordisk Inc $14.5307/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810962715 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.3106/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850295375 CMS
AbbVie Inc. $14.9306/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794007753 CMS
AstraZeneca Pharmaceuticals LP $15.7406/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829405111 CMS
Bausch Health US, LLC $11.1306/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851580903 CMS
Bausch Health US, LLC $4.5506/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851580907 CMS
AbbVie Inc. $10.3706/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794007749 CMS
Biohaven Pharmaceuticals, Inc. $15.7106/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852419937 CMS
Novo Nordisk Inc $14.0606/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810923159 CMS
Amgen Inc. $7.4606/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825809219 CMS
Merck Sharp & Dohme Corporation $17.4806/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848408111 CMS
Novo Nordisk Inc $120.7806/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811001283 CMS
Novo Nordisk Inc $19.5206/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811080103 CMS
Lilly USA, LLC $12.9206/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818759651 CMS
Antares Pharma, Inc. $21.5906/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827511855 CMS
Amgen Inc. $8.6506/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825809215 CMS
Clarus Therapeutics Inc. $16.4206/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855023383 CMS
Clarus Therapeutics Inc. $1.1206/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855023421 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.6606/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819861515 CMS
Avanir Pharmaceuticals, Inc. $14.7806/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801030389 CMS
Novo Nordisk Inc $9.0206/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811119298 CMS
AbbVie Inc. $11.4906/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794007745 CMS
Bausch Health US, LLC $9.8906/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851580943 CMS
AbbVie Inc. $4.8806/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794007741 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.3506/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763697554 CMS
Janssen Pharmaceuticals, Inc $19.0506/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788975385 CMS
AbbVie Inc. $2.7405/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794007733 CMS
AbbVie Inc. $13.6705/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794007737 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.8505/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850161431 CMS
Novo Nordisk Inc $14.5805/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811001275 CMS
ARBOR PHARMACEUTICALS, INC. $16.4605/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830937867 CMS
Biohaven Pharmaceuticals, Inc. $16.6405/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852419933 CMS
SANOFI-AVENTIS U.S. LLC $16.8605/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843527751 CMS
Abbott Laboratories $21.7105/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815494703 CMS
AstraZeneca Pharmaceuticals LP $15.9005/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829465137 CMS
AbbVie Inc. $6.4305/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794007729 CMS
Janssen Pharmaceuticals, Inc $13.5905/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788975381 CMS
Optinose US, Inc. $17.5605/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851672985 CMS
Amarin Pharma Inc. $15.5005/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815173883 CMS
Acella Pharmaceuticals, LLC $13.1405/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 828331927 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,169.04 153
PY2020 $2,482.52 143
PY2021 $3,801.86 213
PY2022 $3,356.90 180
PY2023 $5,733.30 176
PY2024 $2,761.99 147
PY2025 $1,912.21 99

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $569,684.65 88
PY2024 Principal investigator $551,976.89 135
PY2023 Recipient $63,157.75 12
PY2023 Principal investigator $671,514.40 80
PY2022 Recipient $4,512.37 1
PY2022 Principal investigator $122,961.08 49
PY2021 Recipient $5,000.00 1
PY2021 Principal investigator $202,400.01 41
PY2020 Principal investigator $205,619.67 46
PY2019 Recipient $999.72 11
PY2019 Principal investigator $395,658.51 116

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

88 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $18,497.88 12/31/2025 Non-covered Recipient Entity
OnSite Clinical Solutions
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929225
Principal investigator 1 Merck Sharp & Dohme LLC $274.40 12/31/2025 Non-covered Recipient Entity
OnSite Clinical Solutions
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929227
Principal investigator 1 Incyte Corporation $1,146.40 12/24/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571947
Principal investigator 1 Novo Nordisk AS $1,000.00 12/22/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC
NN9924-4558 No dispute reported 06/30/2026 1214102897
Principal investigator 1 Novo Nordisk AS $1,000.00 12/22/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC
NN9924-4558 No dispute reported 06/30/2026 1214103623
Principal investigator 1 Novo Nordisk AS $500.00 12/22/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC
NN9924-4558 No dispute reported 06/30/2026 1214103661
Principal investigator 1 Novo Nordisk AS $300.00 12/22/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC
NN9924-4558 No dispute reported 06/30/2026 1214104119
Principal investigator 1 Incyte Corporation $3,805.00 12/18/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571954
Principal investigator 1 ModernaTX, Inc. $3,612.60 12/17/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252948914
Principal investigator 1 PFIZER INC. $51,616.50 12/09/2025 Non-covered Recipient Entity
OnSite Clinical Solutions
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCEWEEKLY MET097 IN ADULTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES MELLITUS VESPER2 No dispute reported 06/30/2026 1228723318
Principal investigator 1 Merck Sharp & Dohme LLC $60,405.00 11/24/2025 Non-covered Recipient Entity
OnSite Clinical Solutions
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929223
Principal investigator 1 PFIZER INC. $5,414.84 11/24/2025 Non-covered Recipient Entity
Onsite Clinical Solutions LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228818647
Principal investigator 1 PFIZER INC. $18,370.28 11/20/2025 Non-covered Recipient Entity
Onsite Clinical Solutions LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228818691
Principal investigator 1 ModernaTX, Inc. $57,940.65 11/19/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252948892
Principal investigator 1 ModernaTX, Inc. $486.00 11/19/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252948936
Principal investigator 1 PFIZER INC. $900.00 10/30/2025 Non-covered Recipient Entity
Interspond LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228823343
Principal investigator 1 ModernaTX, Inc. $750.00 10/29/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252948934
Principal investigator 1 ModernaTX, Inc. $3,071.25 10/22/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252948920
Principal investigator 1 ModernaTX, Inc. $1,458.00 09/17/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252948930
Principal investigator 1 ModernaTX, Inc. $250.00 09/05/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252948912
Principal investigator 1 PFIZER INC. $2,547.94 08/27/2025 Non-covered Recipient Entity
Onsite Clinical Solutions LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228827285
Principal investigator 1 ModernaTX, Inc. $19,816.65 08/15/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252948896
Principal investigator 1 PFIZER INC. $2,644.42 07/29/2025 Non-covered Recipient Entity
Interspond LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228828191
Principal investigator 1 ModernaTX, Inc. $6,000.00 07/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252948890
Principal investigator 1 ModernaTX, Inc. $500.00 07/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252948900
Principal investigator 1 ModernaTX, Inc. $31,081.05 07/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252948906
Principal investigator 1 ModernaTX, Inc. $250.00 07/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252948924
Principal investigator 1 ModernaTX, Inc. $5,548.50 07/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252948926
Principal investigator 1 ModernaTX, Inc. $4,772.25 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252948918
Principal investigator 1 PFIZER INC. $20,539.40 06/13/2025 Non-covered Recipient Entity
Onsite Clinical Solutions LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228830397
Principal investigator 1 Incyte Corporation $16.16 06/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571942
Principal investigator 1 ModernaTX, Inc. $10,651.50 05/21/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252948928
Principal investigator 1 ModernaTX, Inc. $43,733.25 05/14/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252948908
Principal investigator 1 Incyte Corporation $300.00 05/08/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571938
Principal investigator 1 PFIZER INC. $9,280.73 04/24/2025 Non-covered Recipient Entity
Interspond LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228832931
Principal investigator 1 ModernaTX, Inc. $8,727.75 04/16/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252948898
Principal investigator 1 Novo Nordisk AS $431.72 03/28/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC
NN9924-4558 No dispute reported 06/30/2026 1214103794
Principal investigator 1 Genentech, Inc. $1,864.25 03/24/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS LLC
Transmission Study household No dispute reported 06/30/2026 1211635454
Principal investigator 1 Genentech, Inc. $986.90 03/24/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS LLC
Transmission Study household No dispute reported 06/30/2026 1211635458
Principal investigator 1 ModernaTX, Inc. $8,289.00 03/19/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252948910
Principal investigator 1 PFIZER INC. $20,481.28 03/13/2025 Non-covered Recipient Entity
Onsite Clinical Solutions LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228831497
Principal investigator 1 PFIZER INC. $4,350.00 03/06/2025 Non-covered Recipient Entity
Onsite Clinical Solutions LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228830881
Principal investigator 1 PFIZER INC. $14,455.50 02/27/2025 Non-covered Recipient Entity
INTERSPOND LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228831789
Principal investigator 1 Novo Nordisk AS $628.87 02/21/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC
NN9924-4558 No dispute reported 06/30/2026 1214102315
Principal investigator 1 ModernaTX, Inc. $7,350.75 02/19/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252948916
Principal investigator 1 ModernaTX, Inc. $8,575.20 02/19/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252948922
Principal investigator 1 PFIZER INC. $7,009.46 02/13/2025 Non-covered Recipient Entity
Onsite Clinical Solutions LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228831444
Principal investigator 1 ModernaTX, Inc. $750.00 02/12/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252948894
Principal investigator 1 ModernaTX, Inc. $250.00 02/12/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252948902
Principal investigator 1 ModernaTX, Inc. $250.00 02/12/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252948904
Principal investigator 1 Incyte Corporation $2,506.00 02/06/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571967
Principal investigator 1 PFIZER INC. $38,952.74 01/23/2025 Non-covered Recipient Entity
INTERSPOND LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228831784
Principal investigator 1 ModernaTX, Inc. $18,407.25 01/22/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252948932
Principal investigator 1 Incyte Corporation $5,158.80 01/16/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571961
Principal investigator 1 PFIZER INC. $13,942.38 01/16/2025 Non-covered Recipient Entity
Onsite Clinical Solutions LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228831488
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,645.73 01/15/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185547597
Principal investigator 1 Incyte Corporation $9.18 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571744
Principal investigator 1 Incyte Corporation $279.90 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571750
Principal investigator 1 Incyte Corporation $60.58 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571756
Principal investigator 1 Incyte Corporation $60.58 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571762
Principal investigator 1 Incyte Corporation $9.18 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571766
Principal investigator 1 Incyte Corporation $31.52 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571774
Principal investigator 1 Incyte Corporation $3.60 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571779
Principal investigator 1 Incyte Corporation $74.64 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571787
Principal investigator 1 Incyte Corporation $9.32 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571793
Principal investigator 1 Incyte Corporation $9.32 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571796
Principal investigator 1 Incyte Corporation $98.72 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571803
Principal investigator 1 Incyte Corporation $4.32 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571808
Principal investigator 1 Incyte Corporation $4.32 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571814
Principal investigator 1 Incyte Corporation $5.40 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571821
Principal investigator 1 Incyte Corporation $5.40 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571828
Principal investigator 1 Incyte Corporation $52.48 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571832
Principal investigator 1 Incyte Corporation $31.52 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571838
Principal investigator 1 Incyte Corporation $2.16 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571845
Principal investigator 1 Incyte Corporation $2.16 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571850
Principal investigator 1 Incyte Corporation $9.32 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571854
Principal investigator 1 Incyte Corporation $4.66 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571860
Principal investigator 1 Incyte Corporation $4.66 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571866
Principal investigator 1 Incyte Corporation $1.20 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571873
Principal investigator 1 Incyte Corporation $1.20 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571882
Principal investigator 1 Incyte Corporation $6.60 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571886
Principal investigator 1 Incyte Corporation $6.60 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571894
Principal investigator 1 Incyte Corporation $1.80 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571901
Principal investigator 1 Incyte Corporation $52.48 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571906
Principal investigator 1 Incyte Corporation $31.52 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571912
Principal investigator 1 Incyte Corporation $31.52 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571916
Principal investigator 1 Incyte Corporation $279.90 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571921
Principal investigator 1 Incyte Corporation $4.66 01/09/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC CHARLOTTE CENTRAL OFFICE
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240571926